US government funds research into psychedelic drug ibogaine

Federal officials have announced new funding to investigate the medical applications of ibogaine, a psychedelic substance. The initiative includes up to $4.9 million to lay the groundwork for the initial U.S. studies of ibogaine specifically for post-traumatic stress disorder (PTSD). Health Secretary Robert F. Kennedy Jr. stated the funds will support the necessary preparations for manufacturing, dosage, and study design, rather than direct patient research. Veterans Affairs Secretary Doug Collins indicated that safety and rigorous research would be the primary focus.

Ibogaine is derived from a shrub native to West Africa. Its use can lead to intense hallucinations, nausea, vomiting, tremors, and potentially fatal irregular heart rhythms. The drug is currently classified as illegal in the U.S., similar to LSD and MDMA. Despite these risks, veterans organizations and advocates for psychedelic treatments assert that ibogaine holds significant potential for treating intractable conditions such as PTSD, severe depression, and opioid addiction. Research in the U.S. has been largely stalled for decades due to the drug's restricted status.

The government will collaborate with Beond Inc., a Texas-based company that has experience treating patients with ibogaine in Mexico, where it is not illegal. Beond Inc. will provide data and treatment guidance. This announcement follows an April executive order from the Trump administration directing federal agencies to expedite the review and research of psychedelics for mental health conditions. The Food and Drug Administration currently has three other psychedelic applications under review, including those for psilocybin and MDMA.

Disagreement on funding source

The psychedelicalpha.com report states the U.S. Department of Health and Human Services (HHS) provided an update on psychedelics-related initiatives, committing to fund a $20 million real-world evidence network. The other reports specify the funding amount as up to $4.9 million for preparing U.S. studies of ibogaine for PTSD.

What the coverage left out

None of the left-rated or centre-rated reports mention the specific figure of $20 million for a real-world evidence network that was reported by psychedelicalpha.com. Additionally, none of the reports detail the specific reason for Veterans Affairs Secretary Doug Collins's absence from the press conference, as stated in the psychedelicalpha.com digest.